GlassScriptPhysician profile
Niel Naresh Dave
NPI 1487187761
$22,598.28
in general payments reported to CMS, 2019-2025
28 companies · $8,620 in 2025
The $8,620 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.79 · 2021: $142 · 2022: $366 · 2023: $719 · 2024: $13K · 2025: $8,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $6,682 · Travel and Lodging: $215 · Education: $89.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,050.00 |
| Food and Beverage | $6,682.48 |
| Travel and Lodging | $215.24 |
| Education | $89.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16,114.80 | 2024-2025 | Voquezna |
| Abbvie INC. | $976.37 | 2021-2025 | |
| Genzyme Corporation | $649.20 | 2023-2025 | |
| Gilead Sciences, INC. | $614.62 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.59 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $568.43 | 2024-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.49 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $377.08 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $242.86 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $230.52 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $224.30 | 2025 | Sucraid |
| Lilly USA, LLC | $217.34 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $208.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $177.13 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $167.45 | 2023-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $166.10 | 2024-2025 | Zenpep |
| Convatec INC. | $114.70 | 2024 | |
| Pfizer INC. | $104.20 | 2024-2025 | |
| Boston Scientific Corporation | $89.64 | 2023 | Resolution 360 Clip |
| Ipsen Biopharmaceuticals, INC | $84.72 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $64.34 | 2022-2024 | Talicia |
| Ironwood Pharmaceuticals, INC | $48.98 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $40.62 | 2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.75 | 2023 | Cyltezo |
| Digestive Care, INC. | $27.04 | 2024 | Pertzye |
| Intra-Sana Laboratories | $20.68 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Braintree Laboratories, INC. | $17.96 | 2025 | Suflave, Sutab |
| Echosens North America, INC. | $14.69 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niel Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.